Stocks / NASDAQ / Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc.

Our Opinion

Indaptus Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“Both animal studies and a prospective double-blind study in patients with PD confirm that continuous delivery of LD is associated with a reduced risk of motor complications.” (Page 1) Read the full document

Company Description

Indaptus Therapeutics, Inc, is a pre-clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development.

Company Website: